Compare American Water Works Company Inc (AWK) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs Heron Therapeutics Inc — how do they compare? American Water Works Company Inc trades at $135.3 (market cap $26.92B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: American Water Works Company Inc is far larger — about 424.5× Heron Therapeutics Inc's market cap, and American Water Works Company Inc pays a 2.64% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AWK | HRTX | |
|---|---|---|
Market Cap | $26.92B | $63.41M |
Sector | Utilities | Health |
52-Week High | $146.20 | $1.49 |
52-Week Low | $121.13 | $0.33 |
Enterprise Value | $42.78B | $161.31M |
Dividend Yield | 2.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AWK trades at $135.31, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $1.61, beating estimates, while Q1 and Q4 2025 missed. Revenue grew to $5.14B in 2025 with a 21.35% net margin. Analyst consensus is mixed with 14 Buy, 14 Hold, and 2 Sell ratings, targeting $139.83. Recent news highlights operational excellence awards and customer base expansion through acquisitions.
Outlook remains stable with consistent dividend payments and guided EPS growth. Risks include rising debt levels and regulatory pressures. The stock offers steady income and moderate growth potential, but investors should monitor execution on earnings targets and capital expenditure efficiency.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
